Insulin and Insulin-like Growth Factor II Differentially Regulate Endocytic Sorting and Stability of Insulin Receptor Isoform A
Overview
Authors
Affiliations
The insulin receptor isoform A (IR-A) binds both insulin and insulin-like growth factor (IGF)-II, although the affinity for IGF-II is 3-10-fold lower than insulin depending on a cell and tissue context. Notably, in mouse embryonic fibroblasts lacking the IGF-IR and expressing solely the IR-A (R-/IR-A), IGF-II is a more potent mitogen than insulin. As receptor endocytosis and degradation provide spatial and temporal regulation of signaling events, we hypothesized that insulin and IGF-II could affect IR-A biological responses by differentially regulating IR-A trafficking. Using R-/IR-A cells, we discovered that insulin evoked significant IR-A internalization, a process modestly affected by IGF-II. However, the differential internalization was not due to IR-A ubiquitination. Notably, prolonged stimulation of R-/IR-A cells with insulin, but not with IGF-II, targeted the receptor to a degradative pathway. Similarly, the docking protein insulin receptor substrate 1 (IRS-1) was down-regulated after prolonged insulin but not IGF-II exposure. Similar results were also obtained in experiments using [NMeTyr(B26)]-insulin, an insulin analog with IR-A binding affinity similar to IGF-II. Finally, we discovered that IR-A was internalized through clathrin-dependent and -independent pathways, which differentially regulated the activation of downstream effectors. Collectively, our results suggest that a lower affinity of IGF-II for the IR-A promotes lower IR-A phosphorylation and activation of early downstream effectors vis à vis insulin but may protect IR-A and IRS-1 from down-regulation thereby evoking sustained and robust mitogenic stimuli.
Mrazkova L, Lubos M, Voldrich J, Kuzmova E, Zrubecka D, Gwozdiakova P PLoS One. 2024; 19(9):e0309726.
PMID: 39264940 PMC: 11392399. DOI: 10.1371/journal.pone.0309726.
Insulin receptor alternative splicing in breast and prostate cancer.
Li J, Huang G Cancer Cell Int. 2024; 24(1):62.
PMID: 38331804 PMC: 10851471. DOI: 10.1186/s12935-024-03252-1.
Chrudinova M, Kirk N, Chuard A, Venugopal H, Zhang F, Lubos M Mol Metab. 2024; 80:101863.
PMID: 38182007 PMC: 10831276. DOI: 10.1016/j.molmet.2023.101863.
Galal M, Alouch S, Alsultan B, Dahman H, Alyabis N, Alammar S Int J Mol Sci. 2023; 24(19).
PMID: 37834454 PMC: 10573852. DOI: 10.3390/ijms241915006.
Non-glycosylated IGF2 prohormones are more mitogenic than native IGF2.
Potalitsyn P, Mrazkova L, Selicharova I, Tencerova M, Ferencakova M, Chrudinova M Commun Biol. 2023; 6(1):863.
PMID: 37598269 PMC: 10439913. DOI: 10.1038/s42003-023-05239-6.